Related Experiment Video

Updated: Jul 15, 2026

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
09:47

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery

Published on: June 2, 2022

Age is of influence on midazolam requirements in a paediatric intensive care unit

Dana-Anne H de Gast-Bakker1, Suzanne D van der Werff, Renate Sibarani-Ponsen

  • 1Department of Paediatric Intensive Care, VU Medical Center, Amsterdam, The Netherlands.

Acta Paediatrica (Oslo, Norway : 1992)
|April 5, 2007
PubMed

Insights

Children aged 1-4 years require higher midazolam doses for sedation during mechanical ventilation. Midazolam alone is an ineffective sedative for all pediatric intensive care unit patients.

Area of Science:

  • Pediatric critical care medicine
  • Pharmacology
  • Anesthesiology

Background:

  • Sedation is crucial for critically ill children requiring mechanical ventilation.
  • Midazolam is commonly used for sedation in pediatric intensive care units (PICUs).
  • Age-related differences in drug metabolism and response are well-documented in pediatric populations.

Purpose of the Study:

  • To investigate the influence of age on midazolam requirements in critically ill children.
  • To compare midazolam dosages across different pediatric age groups.
  • To evaluate the efficacy of midazolam as a sole sedative agent.

Main Methods:

  • Retrospective observational study of 58 children (28 days-18 years) requiring mechanical ventilation for at least 5 days.
  • Children were categorized into three age groups: 28 days-1 year, 1-4 years, and older than 4 years.
  • Midazolam dosage and sedative efficacy were analyzed over a 5-day period.

Main Results:

  • Children aged 1-4 years required the maximum midazolam dosage (0.3 mg/kg/h) within 2 days.
  • This age group exhibited higher mean total midazolam doses throughout the study period.
  • By day 5, midazolam monotherapy was insufficient for sedation in all children aged 1-4 years.

Conclusions:

  • Children aged 1-4 years necessitate higher midazolam dosages compared to younger and older children.
  • Midazolam alone demonstrates limited efficacy as a sedative agent for all pediatric age groups.
  • Further research is needed to understand age-related mechanisms affecting midazolam requirements and its role in PICU sedation.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...